Vanguard Health Care ETF

Latest Vanguard Health Care ETF News and Updates

  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Emerging Markets Drive Abbott’s Nutritional Business Growth

    In 1Q17, Abbott Laboratories’ (ABT) Nutritional segment reported revenue of nearly $1.6 billion, a year-over-year (or YoY) fall of ~1%.

    By Margaret Patrick
  • uploads///generic drug savings
    Company & Industry Overviews

    Will Generic Drugs Help Curb Healthcare Costs?

    Reducing medical costs would be a high priority in all economies, and generic drugs could provide a solution.

    By VanEck
  • uploads///patent cliff
    Company & Industry Overviews

    Drug Patent Expirations: $190 Billion Is Up for Grabs

    According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.

    By VanEck
  • uploads///Graph
    Earnings Report

    Universal Health Services’ Net Profit Margin Expected to Rise

    Wall Street analysts expect that Universal Health Services (UHS) will report higher net profit margins in 3Q15 compared to margins in 3Q14.

    By Margaret Patrick
  • Mounting Evidence of Inflation Firming Up
    Real Insights

    Mounting Evidence of Inflation Firming Up

    The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index jumped to a 14-year high…

    By VanEck
  • uploads///calculator _
    Consumer

    How to Invest Like Jeff Bezos: The Top Three Sectors to Watch

    Jeff Bezos’s primary focus remains his role as the CEO of Amazon, but he’s made investments in many other industries and companies.

    By Jitendra Parashar
  • uploads///Chart
    Company & Industry Overviews

    Changes in Johnson & Johnson’s Profit Margins in 4Q17

    Johnson & Johnson’s gross profit margin decreased to 64.1% in 4Q17, a ~5% decrease compared to 69.1% in 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Estimates for Eli Lilly’s 4Q17 Earnings

    Eli Lilly (LLY) plans to release its 4Q17 and 2017 earnings on January 31, 2018. For 4Q17, analysts expect LLY to report earnings per share of $1.07 on revenues of ~$5.9 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Are Pfizer’s Positive Growth Contributors?

    Lurica, one of the blockbuster drugs from Pfizer’s portfolio, is expected to report revenue growth during 4Q17—likely driven by increased US sales.

    By Mike Benson
  • uploads///ARWR TRiM platform
    Company & Industry Overviews

    What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?

    Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.

    By Kenneth Smith
  • uploads///Chart  CIR
    Company & Industry Overviews

    Merck & Co.’s Cardiovascular and Immunology Products in 3Q17

    In Merck’s cardiovascular product portfolio, Adempas reported revenues of $70 million in 3Q17 compared to $48 million in 3Q16.

    By Mike Benson
  • uploads///Chart  Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceutical Segment: 4Q17 Estimates

    For 4Q17, revenues for Johnson & Johnson’s immunology franchise are expected to increase due to the strong performance of Stelara.

    By Mike Benson
  • uploads///Insys priorities
    Company & Industry Overviews

    Insys Has Legal Issues Galore

    In December 2016, the U.S. Attorney’s office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees.

    By Kenneth Smith
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Eli Lilly’s Neuroscience Products Portfolio in 3Q17

    Eli Lilly’s Strattera had revenues of $137 million in 3Q17, a decline of ~31% compared to $199 million in 3Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Pfizer Expects Eucrisa to Report Sales of ~$2.0 Billion

    Eucrisa growth trends On December 14, 2016, Pfizer (PFE) announced that it had secured FDA approval for its mild-to-moderate AD (atopic dermatitis) therapy, Eucrisa (crisaborole) 2% ointment, for patients over two years old. This drug was added to Pfizer’s portfolio through the acquisition of Anacor Pharmaceuticals, which was completed in June 2016 for ~$5.2 billion. […]

    By Margaret Patrick
  • uploads///Alimta
    Company & Industry Overviews

    An Update on Eli Lilly’s Oncology Drugs: Alimta, Erbitux, and Gemzar

    In 3Q17, Eli Lilly’s (LLY) Alimta generated revenues of $514.5 million, a ~10% increase on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Recent Developments for Merck’s Keytruda

    Merck & Co.’s (MRK) Keytruda (pembrolizumab) sales increased ~194% in 3Q17 to ~$1.1 billion.

    By Mike Benson
  • uploads///Chart  Cardio
    Company & Industry Overviews

    Eli Lilly’s Cialis and Other Cardiovascular Products in 3Q17

    Eli Lilly’s cardiovascular franchise includes the drugs Cialis and Effient, but for 3Q17, both drugs reported lower sales.

    By Mike Benson
  • uploads///stock price
    Company & Industry Overviews

    Intuitive Surgical’s Recent Stock Split: The Market Reaction

    On October 6, 2017, Intuitive Surgical will start trading on a split-adjusted basis. It has scheduled a stock split for its shares in a ratio of 3:1.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Medtronic Focused on Efficacy and Safety of LVAD Offerings

    Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.

    By Margaret Patrick
  • uploads///
    Industrials

    What Stocks Should Be on Your Radar amid Geopolitical Tensions

    Renewed tensions arising out of North Korea’s missile launch on Tuesday had a major impact on volatility. Asian markets have declined more than 1% as risk aversion dominated markets.

    By Ricky Cove
  • uploads///Chart  Dev
    Company & Industry Overviews

    Key Developments for Allergan in 2Q17

    Allergan (AGN) is a leading pharmaceuticals company involved with pharmaceuticals, over-the-counter products, eye care, and aesthetics products.

    By Mike Benson
  • uploads///Vectibix revenues
    Company & Industry Overviews

    What We May See from Amgen’s Vectibix in 2017

    Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]

    By Daniel Collins
  • uploads///
    Miscellaneous

    Which Stocks Will Benefit the Most from US-Korea Tensions?

    Some companies benefit in times of uncertainty, and some sectors provide cover for investors.

    By Ricky Cove
  • uploads///Upadacitinib
    Company & Industry Overviews

    Upadacitinib: Opportunity for AbbVie’s Long-Term Growth?

    ABBVie anticipates upadacitinib to be commercialized by 2019. If approved, AbbVie’s upadacitinib will directly compete with Pfizer’s (PFE) Xeljanz.

    By Daniel Collins
  • uploads/// Bayer
    Real Insights

    How Bayer Is Creating Value through Innovation

    In 2016, Bayer owned ~51,000 valid patent applications and patents relating to ~5,000 protected inventions worldwide.

    By VanEck
  • uploads///Chart  Checkmate
    Company & Industry Overviews

    Data from the Checkmate-205 Study Evaluating Opdivo

    Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Duodopa Revenues
    Company & Industry Overviews

    A Look at AbbVie’s Neuroscience Portfolio

    In 2016, AbbVie’s (ABBV) Duodopa, a combination drug for the treatment of advanced Parkinson’s disease, generated revenue of ~$293 million.

    By Daniel Collins
  • uploads///Chart  Neuro
    Company & Industry Overviews

    Performance of Eli Lilly’s Neuroscience Products in 1Q17

    Strattera, a drug for the treatment of ADHD, reported 4% growth in its 1Q17 revenues to $196.2 million, compared to $188.1 million for 1Q16.

    By Mike Benson
  • uploads///asia pacific
    Company & Industry Overviews

    How Long Can Thermo Fisher Scientific’s Asia-Pacific Growth Momentum Last?

    Thermo Fisher Scientific (TMO) has a presence around the globe, but around 80% of its revenues are generated from developed markets.

    By Sarah Collins
  • uploads///Chart  Pharmaceuticals
    Company & Industry Overviews

    How JNJ’s Pharmaceuticals Segment Performed in 1Q17

    Johnson & Johnson’s Ppharmaceuticals segment includes products from various franchises: cardiovascular and metabolics, immunology, infectious disease, neuroscience, and oncology.

    By Mike Benson
  • uploads///Medical Devices Market Share as of
    Macroeconomic Analysis

    Is Medical Technology Driving the US Healthcare Industry?

    The US medical device industry is a global leader. Its market was valued at ~$140 billion for 2016. It represents ~45% of the global market.

    By Mary Sadler
  • uploads///Rising Contribution in Private Health Insurance
    Macroeconomic Analysis

    Rising Costs Are a Major Issue in the Healthcare Sector

    The US economy is dealing with rising healthcare costs. The national healthcare expenditure grew 5.8% to $3.2 trillion in 2015 or $9,990 per person.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Keytruda Saw Impressive Growth in 2016

    Keytruda, a prescription medicine classified under Merck’s (MRK) immunooncology franchise, is used to treat non-small cell lung cancer as well as melanoma.

    By Mike Benson
  • uploads///Chart  NewProducts
    Company & Industry Overviews

    Eli Lilly and Co.’s New Products Portfolio

    In 4Q16, Eli Lilly (LLY) reported Basaglar sales of $40 million from Japan and several European markets.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Innovative Health and Essential Health in 4Q16

    Pfizer’s (PFE) portfolio includes medicines, vaccines, and consumer healthcare products. It segregates its operations into Innovative Health and Essential Health.

    By Mike Benson
  • uploads///XLV
    Company & Industry Overviews

    Is the 2017 Outlook for Healthcare Optimistic?

    The healthcare sector provided unimpressive returns in 2016. The Health Care Select Sector SPDR ETF fell 2.5% in 2016.

    By Sarah Sands
  • uploads///Chart
    Earnings Report

    Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug

    Bristol-Myers Squibb’s revenues from Opdivo are estimated to be $938.8 million in 3Q16, as compared to $305 million in 3Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Innovative Health and Essential Health Businesses

    Pfizer’s businesses Pfizer’s (PFE) portfolio comprises medicine, vaccines, and consumer healthcare products. The company has segregated its operations into two businesses: Innovative Health and Essential Health. Business segments  The above chart shows revenues for the last few quarters and revenue estimates for the next two quarters. Pfizer’s Innovative Health segment, which was previously referred to as […]

    By Mike Benson
  • uploads///Risks
    Company & Industry Overviews

    What Are Pfizer’s Additional Risks?

    Pfizer (PFE) faces foreign exchange, global, legal, and integration risks. These risks are in addition to the pharmaceutical industry’s risks.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Existing Chemotherapy Drugs for Lymphoma

    Opdivo is under phase II study for the use in the treatment of relapsed or refractory classical Hodgkin’s lymphoma.

    By Mike Benson
  • uploads///BusineseCycle_Chart
    Macroeconomic Analysis

    Business Cycle Perspective: Has the Healthcare Sector Hit Bottom?

    This year, the healthcare sector seems to be receding, and the utilities sector seems to be in good gear. This is a sign that the early bear phase is over.

    By Surbhi Jain
  • uploads///Graph
    Earnings Report

    Humana Acquisition Could Be Aetna’s Key Long-Term Growth Driver

    Aetna’s Humana acquisition is mainly aimed at increasing the combined companies’ exposure to the high-growth Medicare business. The deal is currently being scrutinized by antitrust regulators.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    The Pfizer–Allergan Deal: 4Q15 Brings the Biggest Pharma Merger

    The Pfizer–Allergan deal could be beneficial to the combined entity in different ways. The combined entity has innovative and established product portfolios.

    By Mike Benson
  • uploads///marketing and sales
    Company & Industry Overviews

    Assessing Medtronic’s Marketing and Sales Strategy in 2015

    To extend cost-effective, high-quality medical devices and therapies, Medtronic aims to organize its marketing and sales teams around physician preferences.

    By Sarah Collins
  • uploads///Keytruda
    Earnings Report

    Keytruda: Hope for Merck’s Immuno-Oncology Franchise

    Keytruda is a prescription medicine. It’s in Merck & Co.’s (MRK) immuno-oncology franchise. The drug treats non-small cell lung cancer and melanoma.

    By Mike Benson
  • uploads///Remicade
    Earnings Report

    Remicade: A Falling Drug in Merck’s Immunology Franchise

    Remicade is one of the blockbuster drugs for Merck & Co. (MRK). It’s one of the top-selling drugs for the treatment of inflammatory disorders.

    By Mike Benson
  • uploads///Gardusil
    Earnings Report

    Gardasil Is Driving Merck’s Vaccine Business

    The Gardasil franchise is Merck & Co.’s (MRK) leading vaccine franchise. Gardasil is a vaccine that prevents certain strains of HPV (human papillomavirus).

    By Mike Benson
  • uploads///Januvia and Janumet
    Earnings Report

    Januvia and Janumet: Merck’s Blockbuster Diabetes Products

    Januvia and Janumet are two blockbuster drugs in Merck & Co.’s diabetes franchise. They’re used to lower the blood sugar level in patients with type-2 diabetes.

    By Mike Benson
  • uploads///Segmentwise Revenues
    Earnings Report

    Changes in Merck & Co.’s Reported Business Segments in 2015

    The Global Human Health, or Pharmaceuticals, segment generates the most revenue for Merck. It contributed nearly 85% of the total revenue in 2014.

    By Mike Benson
  • uploads///GEP Segment
    Company & Industry Overviews

    Pfizer’s Global Established Pharmaceutical Segment

    The Global Established Pharmaceutical segment deals with products that have or are expected to lose market exclusivity through 2015 in most major markets.

    By Mike Benson
  • uploads///Segmentwise Revenue
    Company & Industry Overviews

    Analyzing Pfizer’s Business Segments

    Pfizer (PFE) is one of the oldest and largest pharmaceutical companies in the US. The company deals in two major business segments.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    A Key Overview of Aetna, One of the Largest Insurance Providers

    With a market capitalization of $35.1 billion, Aetna (AET) is one of the largest insurance providers in the US.

    By Margaret Patrick
  • uploads///covidien
    Fund Managers

    Chilton Investment Company raises its stake in Covidien plc

    Chilton Investment added to its position in Covidien plc (COV) in 4Q14. The position accounts for 3.22% of the fund’s 4Q14 portfolio, up from 0.49% in 3Q14.

    By Adam Rogers
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.